Department of Dermatology, Rabin Medical Center, Beilinson Hospital Petach Tikva, Petach Tikva 49100, Israel. E-mail:
Acta Derm Venereol. 2020 Oct 19;100(18):adv00322. doi: 10.2340/00015555-3669.
Cutaneous leishmaniasis poses a therapeutic challenge in the paediatric population. The aim of this study was to assess the efficacy and safety of miltefosine treatment for Old World cutaneous leishmaniasis in paediatric patients. A multicentre retrospective review of 10 children (≤ 18 years of age) with cutaneous leishmaniasis treated with miltefosine in Israel was performed. Mean ± standard deviation age at diagnosis was 9.1 ± 5.0 years. The Leishmania species diagnosed was L. tropica in 8 cases and Leishmania major in 2 cases. Mean ± standard deviation duration of treatment was 44.8 ± 20.6 days, with a mean follow-up period of 12.1 ± 17.1 months. Complete response was noted in 8 (80%) patients. Treatment failure was noted in 2 (20%) cases. Side-effects related to the medication were minimal. In conclusion, oral miltefosine may be an effective and safe treatment for Old World cutaneous leishmaniasis caused by Leishmania tropica or Leishmania major in children. However, further studies are warranted to draw a definite conclusion.
皮肤利什曼病在儿科人群中带来了治疗挑战。本研究旨在评估米替福新治疗儿童旧世界皮肤利什曼病的疗效和安全性。对以色列 10 名（≤18 岁）接受米替福新治疗的皮肤利什曼病患儿进行了多中心回顾性研究。诊断时的平均年龄±标准差为 9.1±5.0 岁。诊断的利什曼原虫物种为 8 例热带利什曼原虫和 2 例利什曼原虫 major。平均治疗时间±标准差为 44.8±20.6 天，平均随访时间为 12.1±17.1 个月。8 例（80%）患者完全缓解。2 例（20%）患者治疗失败。与药物相关的副作用很小。总之，口服米替福新可能是治疗儿童由热带利什曼原虫或利什曼原虫 major 引起的旧世界皮肤利什曼病的一种有效且安全的方法。然而，需要进一步的研究来得出明确的结论。
